Replimune Group, Inc.
NASDAQ: REPL0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sushil Patel
- Employees
- 479
- Headquarters
- Woburn, United States
- IPO year
- 2018
- Market cap
- $930.6M
- Website
- https://www.replimune.com
Loading REPL…
Loading profile data…Frequently asked questions about REPL
What does Replimune Group, Inc. (REPL) do?
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experim...
Where does REPL trade?
Replimune Group, Inc. (REPL) trades on the NASDAQ Global Select.
What sector is REPL in?
Replimune Group, Inc. (REPL) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Replimune Group, Inc.?
Sushil Patel is the chief executive officer of Replimune Group, Inc. (REPL).
Where is Replimune Group, Inc. headquartered?
Replimune Group, Inc. is headquartered in United States.
Does REPL pay a dividend?
Replimune Group, Inc. (REPL) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did REPL go public?
Replimune Group, Inc. (REPL) completed its initial public offering in 2018.